Neurodegenerative Diseases

Coya Therapeutics, Inc. (NASDAQ: COYA), a clinical-stage biotech company developing Treg-targeted therapies for neuroinflammatory diseases, will headline H.C. Wainwright’s BioConnect Conference in New York City on May 16, 2025. CEO Dr. Arun Swaminathan will discuss the integration of its proprietary platforms, including lead compound COYA 302—a dual-pathway subcutaneous treatment combining LD IL-2 and CTLA4-Ig to address neuroinflammation. The company emphasizes its platforms’ potential in neurodegenerative, autoimmune, and metabolic disorders, while noting risks related to clinical timelines, regulation, and capital intensity in SEC filings. A live stream of the conference session will be available on its investor relations page for 90 days.